influenza
pandem
claim
live
pandem
develop
drug
resist
complic
effort
control
treat
widespread
ill
research
util
tradit
chines
medicin
databas
taiwan
tcm
databas
taiwan
screen
compound
simultan
target
overcom
current
difficulti
viru
mutat
top
three
candid
de
novo
deriv
xylopin
rosmaricin
bioactiv
de
novo
deriv
valid
multipl
machin
learn
predict
model
abil
de
novo
compound
maintain
comfacomsia
contour
form
key
interact
impli
bioactiv
within
well
addit
pyridinium
fragment
critic
form
stabl
interact
support
molecular
dynam
md
simul
result
md
hydrophob
interact
torsion
angl
consist
support
find
dock
multipl
anchor
lack
bind
residu
prone
mutat
suggest
tcm
de
novo
deriv
may
resist
drug
resist
advantag
convent
treatment
oseltamivir
result
suggest
tcm
de
novo
deriv
may
suitabl
candid
dualtarget
drug
influenza
first
global
pandem
centuri
announc
world
health
organ
due
worldwid
spread
influenza
subtyp
countri
report
laboratori
confirm
case
death
record
current
neuraminidas
inhibitor
tamifluh
oseltamivir
remain
primari
drug
prescrib
patient
infect
howev
emerg
drug
resist
viral
strain
limit
drug
administr
window
exemplifi
need
addit
therapi
import
constitu
influenza
surfac
membran
protein
includ
hemagglutinin
neuraminidas
matrix
protein
proton
channel
hemagglutinin
mediat
bind
viral
particl
host
cell
surfac
sialic
acid
invas
virus
host
cell
neuraminidas
respons
cleavag
sialic
acid
residu
promot
releas
progeni
virus
proton
channel
critic
viral
mrna
incorpor
virion
viru
bud
one
hundr
serolog
subtyp
identifi
differ
combin
hemagglutinin
nine
neuraminidas
group
current
known
proton
channel
recent
solv
influenza
b
allow
depth
studi
regard
biolog
function
action
mechan
protein
use
target
ration
attempt
design
drug
influenza
viru
strain
tripl
reassort
contain
gene
segment
avian
swine
human
influenza
virus
addit
antigen
shift
lead
fundament
chang
influenza
surfac
antigen
antigen
drift
could
reduc
bind
affin
host
antibodi
antigen
major
challeng
influenza
vaccin
develop
rapid
evolut
influenza
virus
caus
vaccin
easili
outdat
reformul
necessari
year
although
viru
suscept
neuraminidas
inhibitor
case
regard
oseltamivirresist
virus
neuraminidas
mutat
report
given
influenza
virus
rna
genom
prone
chang
imper
devis
new
therapi
much
effort
made
investig
mechan
devis
altern
drug
drugresist
issu
develop
inhibitor
target
antigen
reduc
resist
issu
result
mutat
singl
target
antigen
comput
approach
wide
appli
molecular
biolog
medicin
structurebas
method
includ
dock
md
simul
invalu
tool
influenza
subtyp
pandem
rais
public
concern
due
drug
resist
strain
drug
resist
occur
conform
chang
caus
origin
drug
lose
bind
abil
exhibit
biolog
effect
world
largest
tcm
databas
taiwan
employ
screen
potenti
lead
simultan
bind
three
de
novo
compound
deriv
rosemarinu
officinali
guatteria
amplifolia
identifi
dual
bind
properti
structur
analysi
indic
candid
bind
multipl
residu
addit
de
novo
deriv
predict
bioactiv
use
four
differ
comput
model
compound
valid
potent
dual
target
influenza
drug
candid
multipl
valid
key
advantag
candid
includ
bind
multipl
amino
acid
bind
known
mutat
residu
advantag
reduc
drug
resist
caus
singl
point
mutat
broader
context
featur
import
success
drug
develop
discuss
hope
provid
start
templat
drug
develop
improv
drug
discoveri
design
comput
dock
import
investig
ligandprotein
interact
elucid
bind
mechan
sinc
public
pioneer
paper
establish
lowfrequ
motion
exist
protein
dna
help
reveal
dynam
mechan
underli
fundament
biolog
function
nmr
observ
later
confirm
infer
find
appli
medic
treatment
recent
year
applic
molecular
dynam
investig
intern
motion
biolog
function
biomacromolecul
open
new
frontier
vast
amount
inform
molecular
recognit
bind
conform
conform
chang
molecular
mechan
bioactiv
stabil
drug
discoveri
found
understand
interact
drug
protein
dna
consider
given
static
structur
dynam
inform
obtain
simul
dynam
process
regard
dock
md
simul
util
studi
provid
comprehens
analysi
proteinligand
interact
static
dynam
condit
much
effort
place
develop
new
effect
influenza
treatment
focus
neuraminidas
target
protein
date
hemagglutinin
inhibitor
avail
tradit
chines
medicin
tcm
use
extens
find
effect
drug
success
design
novel
medicin
compound
identifi
potenti
drug
lead
tradit
chines
medicin
databas
taiwan
tcm
taiwan
preliminari
studi
conduct
lab
show
potenti
tcm
compound
serv
neuramindas
hemagglutinin
inhibitor
individu
view
current
need
drug
effect
nativ
mutant
promis
preliminari
result
present
studi
integr
concept
dual
target
aforement
comput
tool
tcm
attempt
identifi
dualtarget
inhibitor
may
use
drug
develop
experiment
procedur
screen
result
filter
step
summar
figur
among
nativ
tcm
compound
dock
use
de
novo
evolut
tabl
de
novo
compound
dual
bind
capac
rank
combin
dockscor
top
ten
deriv
list
tabl
nine
ten
top
rank
de
novo
compound
deriv
rosmaricin
natur
compound
isol
rosemarinu
officinali
remain
de
novo
compound
base
xylopin
natur
found
guatteria
amplifolia
top
three
deriv
common
pyridinium
addit
nativ
structur
figur
pyridinium
addit
could
main
explan
higher
dockscor
three
deriv
compar
nativ
compound
deriv
differ
number
fuse
ring
slight
differ
dockscor
suggest
addit
acycl
ring
littl
influenc
bind
affin
dock
de
novo
compound
back
receptor
provid
insight
modif
made
modul
enhanc
molecular
properti
also
highlight
import
proteinligand
interact
dock
protein
bind
site
interact
via
proton
amino
group
pi
hydrogen
bond
hbond
interact
respect
figur
figur
figur
interact
via
carbonyl
group
group
tamifluh
form
hbond
interact
figur
report
one
major
residu
ligand
bind
site
abil
de
novo
deriv
form
interact
may
account
higher
dockscor
bind
top
three
de
novo
deriv
site
detail
elsewher
abil
bind
import
residu
indic
dual
target
possibl
candid
figur
valu
within
predict
band
r
valu
svm
model
construct
use
ident
molecular
descriptor
ligand
mlr
model
r
valu
svm
model
correl
observ
predict
activ
ligand
illustr
figur
tabl
summar
pic
valu
tamifluh
top
three
candid
predict
gener
mlr
svm
model
predict
activ
tamifluh
use
gener
mlr
model
pic
similar
observ
bioactiv
valu
report
literatur
pic
indic
gener
mlr
model
good
predict
model
predict
activ
valu
use
svm
model
indic
lower
pic
regard
tamifluh
nonetheless
model
indic
tcm
de
novo
deriv
good
candid
neuraminidas
inhibitori
activ
mlr
svm
model
predict
hemagglutinin
inhibitori
activ
establish
due
lack
avail
hemagglutinin
inhibitor
structur
literatur
stabil
profil
analysi
root
mean
squar
deviat
rmsd
total
energi
result
md
summar
figur
provid
inform
complex
ligand
stabil
ns
simul
process
rmsd
four
complex
rang
stabil
ns
total
energi
complex
equilibr
kcalmol
ligand
rmsd
remain
stabl
throughout
simul
evid
chang
total
energi
observ
ns
rmsd
total
energi
stabil
ns
fluctuat
ligand
rmsd
observ
tamifluh
first
ns
chang
observ
ligand
rmsd
total
energi
ns
end
md
larger
ligand
rmsd
fluctuat
higher
total
energi
observ
may
attribut
spatial
structur
dock
characterist
consist
bulki
xylopin
residu
link
way
similar
ci
conform
figur
well
establish
cisconform
less
stabl
transcounterpart
thu
may
explain
higher
total
energi
level
addit
bind
though
aminopyridinium
residu
allow
xylopin
structur
freedom
rotat
therebi
increas
ligand
rmsd
total
energi
level
hbond
network
md
simul
hbond
occup
compound
summar
tabl
figur
distanc
maintain
figur
distanc
glu
also
remain
figur
tabl
tamifluh
form
high
occup
hbond
intriguingli
bond
distanc
profil
indic
one
key
amino
acid
hbond
format
figur
bond
distanc
gener
exceed
thu
explain
low
occup
rate
tabl
tamifluh
distanc
first
ns
decreas
ns
thu
account
low
occup
rate
well
despit
low
occup
rate
bond
distanc
profil
suggest
import
bind
site
tamifluh
possibl
mechan
proteinligand
interact
insight
ligand
stabil
occur
within
protein
bind
site
discern
md
simul
hbond
format
sandwich
aminopyridinium
anchor
figur
howev
xylopin
moieti
remain
unattach
caus
strain
compound
possibl
contribut
larg
hbond
distanc
fluctuat
figur
approxim
ns
attract
caus
termin
amin
residu
torqu
toward
increas
distanc
figur
result
stabl
hbond
lost
addit
hbond
form
end
md
simul
primari
bind
forc
hbond
form
contrast
multipl
bind
site
secur
within
bind
site
reflect
small
hbond
distanc
fluctuat
compar
figur
bound
respect
figur
multipl
attach
point
anchor
aminopyridin
moieti
rosmaricin
moieti
reduc
strain
molecular
structur
reflect
low
total
energi
bond
distanc
fluctuat
increas
bond
distanc
figur
start
ns
due
intermolecular
hbond
format
atom
nh
residu
nonetheless
hbond
maintain
throughout
md
simul
suggest
good
stabil
mechan
stabil
similar
addit
hbond
ident
hbond
form
figur
addit
anchor
point
stabil
residu
avail
rotat
lower
total
energi
compound
figur
within
anchor
ligand
twist
contribut
hbond
fluctuat
figur
stabil
tamiflu
result
bind
anchor
reflect
low
total
energi
profil
figur
small
hbond
distanc
fluctuat
figur
abil
de
novo
deriv
form
stabl
complex
also
assess
de
novo
deriv
capabl
form
hbond
key
bind
site
torsion
angl
flexibl
bond
candid
complex
summar
figur
monitor
bond
stabl
except
e
figur
fluctuat
could
attribut
attract
amin
group
h
atom
asp
bound
b
primari
locat
torqu
chang
record
torsion
angl
chang
b
support
previou
specul
unattach
xylopin
moieti
key
sourc
instabl
torsion
angl
fluctuat
mainli
due
rotat
g
j
figur
chang
expect
h
atom
amin
group
continu
rotat
form
hbond
key
amino
acid
bond
figur
exhibit
similar
characterist
rapid
rotat
amin
group
l
visual
record
angl
trajectori
nag
figur
tamiflu
figur
rel
stabl
intermolecular
torsion
chang
indic
lower
stabil
nag
tamiflu
respect
due
instabl
ligand
structur
may
attribut
weaker
unstabl
ligandprotein
affin
hydrophob
interact
hydrophob
interact
also
play
role
stabil
ligand
within
figur
figur
bind
site
md
due
differ
ligand
structur
bind
conform
amino
acid
hydrophob
interact
form
differ
amino
acid
involv
hydrophob
interact
includ
stabil
interact
includ
hbond
hydrophob
interact
observ
bind
site
figur
tcm
candid
tamiflu
spatial
distribut
hbond
coupl
hydrophob
interact
limit
free
movement
ligand
within
thu
increas
stabil
complex
investig
dock
featur
comfa
comsia
model
built
valid
use
neuraminidas
inhibitor
list
tabl
pl
analys
result
comfa
comsia
model
shown
tabl
comfa
model
gener
use
steric
electrostat
field
yield
tabl
valid
comfa
comsia
map
use
assess
ligand
bioactiv
contour
de
novo
compound
ns
md
simul
rel
spatial
posit
comfa
comsia
featur
map
shown
figur
hbond
group
match
electroposit
group
featur
comfa
model
figur
hbond
donor
featur
comsia
model
figur
hydrophob
benzen
structur
match
steric
favor
region
comfa
map
hydrophob
featur
comsia
map
carbonyl
group
form
hbond
satisfi
hbond
acceptor
featur
comsia
model
tamifluh
also
contour
comfa
comsia
model
group
close
match
steric
favor
region
comfa
figur
hydrophob
featur
comsia
figur
residu
similar
characterist
group
de
novo
deriv
addit
nmethylacetamid
group
tamifluh
form
hbond
locat
near
hbond
donor
featur
comsia
though
compound
contour
inhibitor
featur
identifi
comfa
comsia
critic
differ
observ
tamifluh
tcm
de
novo
deriv
compound
except
tamifluh
form
hbond
primari
bind
site
abil
tcm
de
novo
deriv
maintain
stabl
bind
md
simul
support
potenti
compound
drug
altern
tamifluh
due
lack
report
ligand
bioactiv
literatur
direct
assess
bioactiv
construct
comfa
comsia
model
possibl
altern
indirect
support
provid
assess
abil
de
novo
deriv
maintain
contour
comfacomsia
map
form
interact
key
residu
illustr
figur
tcm
de
novo
deriv
dock
bind
site
form
critic
interact
without
lose
contour
comfa
comsia
map
result
suggest
tcm
de
novo
deriv
capabl
dock
biolog
activ
also
predict
bind
site
thu
possibl
develop
dualtarget
drug
select
de
novo
deriv
import
featur
potenti
inhibitor
summar
figur
salt
bridg
hbond
donor
andor
electrostat
interact
import
characterist
met
potenti
inhibitor
salt
bridg
andor
hbond
format
interact
featur
use
identifi
design
novel
drug
andor
case
tcm
de
novo
deriv
studi
compound
could
structur
fulfil
requir
figur
figur
bind
site
thu
support
potenti
dualtarget
compound
research
identifi
top
three
de
novo
deriv
exhibit
bind
affin
addit
pyridinum
residu
nativ
structur
xylopin
rosmaricin
contribut
bond
format
key
residu
de
novo
deriv
predict
activ
svm
mlr
model
contour
well
model
tcm
de
novo
deriv
abl
maintain
contour
form
key
bind
interact
thu
provid
indirect
support
bioactiv
result
studi
indic
tcm
de
novo
deriv
bind
also
exhibit
biolog
activ
key
bind
locat
de
novo
deriv
includ
mutat
current
attribut
oseltamivir
resist
locat
na
sinc
key
bind
locat
tcm
deriv
overlap
caus
oseltamivir
resist
deriv
abl
bind
virus
current
resist
tamifluh
addit
de
novo
deriv
bind
amino
acid
prone
mutat
tabl
tabl
thu
would
like
abl
exert
activ
across
rang
mutant
virus
last
least
multipl
bond
format
observ
md
provid
addit
insur
possibl
mutat
key
bind
residu
case
singl
point
mutat
de
novo
compound
remain
bound
site
anoth
key
residu
therefor
resist
develop
drug
resist
viru
base
result
observ
studi
tcm
de
novo
deriv
may
attract
compound
design
novel
dualtarget
inhibitor
virtual
screen
de
novo
deriv
gener
molecular
dynam
md
simul
perform
use
discoveri
studio
client
accelri
inc
san
diego
ca
twodimension
threedimension
structur
tcm
compound
gener
use
chembiooffic
perkinelm
inc
cambridg
compar
molecular
field
analysi
comfa
compar
molecular
similar
indic
analysi
comsia
model
construct
use
packag
tripo
inc
st
loui
mo
compound
tcm
databas
taiwan
dock
protein
activ
site
report
previou
studi
procedur
complet
forcefield
chemistri
harvard
molecular
mechan
charmm
virtual
screen
process
perform
use
ligandfit
conform
search
method
base
mont
carlo
algorithm
rigid
bodi
minim
follow
initi
ligand
placement
complet
use
smart
minim
score
function
use
ligandfit
dockscor
tcm
compound
dock
protein
select
rank
sum
dockscor
tamifluh
use
control
dock
score
set
minimum
requir
top
tcm
compound
pass
filter
select
de
novo
evolut
de
novo
evolut
tcm
compound
place
protein
bind
site
describ
previous
ludifrag
attach
nativ
structur
new
deriv
gener
full
evolut
mode
deriv
de
novo
evolut
subject
addit
screen
lipinski
rule
rule
oral
unstabl
pharmacolog
inapplic
compound
de
novo
product
gener
protein
differ
de
novo
product
redock
protein
assess
bind
affin
de
novo
product
dock
protein
select
rank
sum
respect
dockscor
top
ten
compound
highest
dockscor
select
structurebas
analysi
neuraminidas
inhibitor
use
includ
train
set
compound
test
set
compound
adapt
zhang
studi
compound
drawn
use
chembiooffic
perkinelm
inc
cambridg
modifi
physiolog
ioniz
use
prepar
ligand
function
ds
bioactiv
valu
ic
also
obtain
zhang
studi
though
origin
sourc
clarifi
convert
pic
log
ic
molecular
descriptor
compound
calcul
use
calcul
molecular
properti
ds
gfa
use
select
best
repres
molecular
descriptor
util
best
repres
molecular
descriptor
identifi
gfa
mlr
svm
model
construct
use
matlab
mathwork
inc
natick
libsvm
respect
use
predict
bioactiv
tcm
de
novo
compound
md
simul
perform
use
molecular
dynam
packag
ds
complex
creat
solvat
shell
water
around
protein
sodium
cation
ad
system
neutral
minim
use
steepest
descent
conjug
gradient
perform
cycl
proteinligand
complex
gradual
heat
ps
follow
ps
equilibr
phase
product
stage
perform
ns
use
nvt
canon
ensembl
trajectori
frame
save
everi
ps
shake
algorithm
appli
immobil
bond
involv
hydrogen
atom
throughout
md
simul
longrang
electrostat
treat
pme
method
time
step
set
fs
md
stage
temperatur
coupl
decay
time
berendsen
thermal
coupl
method
ps
post
process
trajectori
perform
use
analyz
trajectori
modul
torsion
angl
bond
also
monitor
ds
ligplot
use
gener
schemat
diagram
proteinligand
interact
candid
control
comfa
comsia
model
construct
partial
least
squar
pl
analysi
use
previous
describ
neuraminidas
inhibitor
optim
number
compon
obtain
leaveoneout
method
yield
highest
r
q
valu
noncross
valid
crossvalid
respect
biolog
activ
tcm
de
novo
compound
evalu
base
contour
gener
map
tabl
ha
mutat
point
virus
tabl
na
mutat
point
virus
support
inform
